Cholinesterase inhibitors as Alzheimer's therapeutics
K Sharma - Molecular medicine reports, 2019 - spandidos-publications.com
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …
syndrome of the central nervous system that causes a decline in cognitive function and …
Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014
LS Schneider, F Mangialasche… - Journal of internal …, 2014 - Wiley Online Library
The modern era of drug development for A lzheimer's disease began with the proposal of
the cholinergic hypothesis of memory impairment and the 1984 research criteria for A …
the cholinergic hypothesis of memory impairment and the 1984 research criteria for A …
Alzheimer's disease pharmacotherapy in relation to cholinergic system involvement
GD Stanciu, A Luca, RN Rusu, V Bild… - Biomolecules, 2019 - mdpi.com
Alzheimer's disease, a major and increasing global health challenge, is an irreversible,
progressive form of dementia, associated with an ongoing decline of brain functioning. The …
progressive form of dementia, associated with an ongoing decline of brain functioning. The …
The cholinergic hypothesis of Alzheimer's disease: a review of progress
PT Francis, AM Palmer, M Snape… - Journal of Neurology …, 1999 - jnnp.bmj.com
Alzheimer's disease is one of the most common causes of mental deterioration in elderly
people, accounting for around 50%-60% of the overall cases of dementia among persons …
people, accounting for around 50%-60% of the overall cases of dementia among persons …
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease
A Haake, K Nguyen, L Friedman… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
M Sano, C Ernesto, RG Thomas… - … England Journal of …, 1997 - Mass Medical Soc
Background There is evidence that medications or vitamins that increase the levels of brain
catecholamines and protect against oxidative damage may reduce the neuronal damage …
catecholamines and protect against oxidative damage may reduce the neuronal damage …
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …
specific genes affect drug response. This article highlights current pharmacogenetic …
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
SL Rogers, MR Farlow, RS Doody, R Mohs… - Neurology, 1998 - AAN Enterprises
The efficacy and safety of donepezil as a treatment for patients with mild to moderate
Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients …
Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients …
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
PB Watkins, HJ Zimmerman, MJ Knapp, SI Gracon… - Jama, 1994 - jamanetwork.com
Objective.—To characterize the hepatic effects of tacrine treatment in patients with
Alzheimer's disease. Design.—Controlled trials of tacrine therapy consisting of two blinded …
Alzheimer's disease. Design.—Controlled trials of tacrine therapy consisting of two blinded …
Therapeutic applications of compounds in the Magnolia family
YJ Lee, YM Lee, CK Lee, JK Jung, SB Han… - Pharmacology & …, 2011 - Elsevier
The bark and/or seed cones of the Magnolia tree have been used in traditional herbal
medicines in Korea, China and Japan. Bioactive ingredients such as magnolol, honokiol, 4 …
medicines in Korea, China and Japan. Bioactive ingredients such as magnolol, honokiol, 4 …